e-learning
resources
ERJ
2007
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Eppur si muove, or COPD treatment success and inflammation
Borrill Z., Woodhead M., Soriano J. B., Barnes N. C.
Source:
Eur Respir J 2007; 30: 409-410
Journal Issue:
September
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Borrill Z., Woodhead M., Soriano J. B., Barnes N. C.. Eppur si muove, or COPD treatment success and inflammation. Eur Respir J 2007; 30: 409-410
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Tt anti fibrotiques hors FPI: approche raisonnée / Anti-fibrotic treatments for conditions other than idiopathic pulmonary fibrosis
Source: Virtual Congress 2020 – French programme 2020: Part I
Year: 2020
Anti-interleukin-5 therapy in severe asthma},
Source: Eur Respir Rev 2013; 22: 251-257
Year: 2013
Targeting the IL-1β – IL-17A inflammatory axis for the treatment of viral-induced exacerbations of COPD
Source: Annual Congress 2012 - Animal models of asthma and COPD and late-breaking abstracts on RCT in asthma and COPD
Year: 2012
Thermoplastie bronchique : indications actuelles / Asthma thermoplasty: current indications
Source: Virtual Congress 2021 – French programme 2021
Year: 2021
COPD: not just a respiratory disease!
Source: Eur Respir J 2006; 28: Suppl. 50, 105s
Year: 2006
LATE-BREAKING ABSTRACT: Stratification of patients with COPD by frequence of exacerbations is an essential step for what to treat in COPD. - A survey in a real life COPD population
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013
Indacaterol/glycopyrronium (IND/GLY) reduces exacerbation and improves lung function versus salmeterol/fluticasone (SFC) in patients with and without prior ICS use: The FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
LATE-BREAKING ABSTRACT: Eosinophilic inflammation in COPD: During clinical stability and exacerbations. The AERIS study
Source: International Congress 2015 – The relevance of diagnostic and monitoring tools in clinical practice
Year: 2015
Implications of under treatment of stable COPD (SAVING study)
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
Exacerbations and hospitalizations due to exacerbations in asthma-COPD overlap sindrome (ACOS) in PUMA study
Source: International Congress 2016 – Asthma, COPD, and ACOS: physical activity, dietary aspects, and diseases burden
Year: 2016
RT protocol reduces AECOPD readmissions
Source: International Congress 2016 – In-patient and out-patient COPD management
Year: 2016
Indacaterol/glycopyrronium (IND/GLY) is more effective than salmeterol/fluticasone (SFC) in reducing exacerbations, regardless of outcome measurement utilised: Results from the FLAME study
Source: International Congress 2016 – Novel insights into the treatment of COPD
Year: 2016
Indacaterol/glycopyrronium (IND/GLY) reduces exacerbations compared with salmeterol/fluticasone (SFC) in various sub-groups from the FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Mucoviscidose: enfin des traitements ciblés / Cystic fibrosis: targeted therapies, at last !
Source: Virtual Congress 2020 – French programme 2020: Part I
Year: 2020
Severe refractory asthma: an update},
Source: Eur Respir Rev 2013; 22: 227-235
Year: 2013
Heliox administration in patients with COPD exacerbation – Technical aspects
Source: Annual Congress 2010 - Mechanical ventilation and weaning
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept